A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Financial Summary
| Share Statistics | VOGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $410.8 | $646.7 | 35% |
|
| Shares Out (Mil) | 5.5 | 44.2 | 14% |
|
| Institutional Ownership | 5.0% | 85.5% | 5% |
|
| Float (Mil) | 8.9 | 47.3 | 18% |
|
| Beta | na | 0.69 | na |
|
| Avg Daily Volume (000s) | 343 | 391 | 52% |
|
| Price Change (52-week) |
na | 69.0% | na |
|
| Growth | VOGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | VOGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $291 | na |
|
| Net Income (TTM) (Mil) | ($2) | ($11) | 37% |
|
| EPS (TTM) | ($0.287) | ($0.700) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($1) | ($6) | 30% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $182 | $463 | 26% |
|
| Valuation | VOGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.81 | na |
|
| P/E | na | 17.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | VOGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.1% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (348.2%) | (23.4%) | 1% |
|
| ROE | 223.5% | (20.6%) | 98% |
|
| Liabilities to Assets | 255.8% | 32.0% | 99% |
|
| F-Score | 1 | 3 | na |
|
Vogenx, Inc. did not pass any screens on 8/21/2026.
